177 related articles for article (PubMed ID: 32584958)
21. The Early Clinical Response Endpoint: Great Timing by the Food and Drug Administration?
Talbot GH
Clin Infect Dis; 2017 Jan; 64(2):218-220. PubMed ID: 28003217
[No Abstract] [Full Text] [Related]
22. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
McCurdy S; Nenninger A; Sheets A; Keedy K; Lawrence L; Quintas M; Cammarata S
Int J Infect Dis; 2020 Aug; 97():374-379. PubMed ID: 32534142
[TBL] [Abstract][Full Text] [Related]
23. Overview of recent studies of community-acquired pneumonia.
Higgins K; Singer M; Valappil T; Nambiar S; Lin D; Cox E
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S150-6. PubMed ID: 18986282
[TBL] [Abstract][Full Text] [Related]
24. The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance.
Peyrani P; Mandell L; Torres A; Tillotson GS
Expert Rev Respir Med; 2019 Feb; 13(2):139-152. PubMed ID: 30596308
[TBL] [Abstract][Full Text] [Related]
25. A Review of Newly Approved Antibiotic Treatment for Community-Acquired Bacterial Pneumonia: Lefamulin.
Wang H; Charles CV
Sr Care Pharm; 2020 Aug; 35(8):349-354. PubMed ID: 32718391
[TBL] [Abstract][Full Text] [Related]
26. Managing community-acquired pneumonia during flu season.
Haessler S; Schimmel JJ
Cleve Clin J Med; 2012 Jan; 79(1):67-78. PubMed ID: 22219236
[TBL] [Abstract][Full Text] [Related]
27. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
[TBL] [Abstract][Full Text] [Related]
28. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
Echols RM; Tillotson GS; Song JX; Tosiello RL
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S166-75. PubMed ID: 18986284
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Canut A; Isla A; Rodríguez-Gascón A
Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
[TBL] [Abstract][Full Text] [Related]
30. Omadacycline in Skin Infections and Pneumonia: A Review of the Evidence.
Vacalis S; Brunton S; Gindi J
J Fam Pract; 2022 Jun; 71(5 Suppl):S10-S21. PubMed ID: 35776862
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB
Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059
[TBL] [Abstract][Full Text] [Related]
32. Solithromycin monotherapy for treatment of community-acquired bacterial pneumonia: A meta-analysis of randomised controlled trials.
Wen J; Chen F; Zhao M; Wang X
Int J Clin Pract; 2019 May; 73(5):e13333. PubMed ID: 30810253
[TBL] [Abstract][Full Text] [Related]
33. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Jorgenson MR; DePestel DD; Carver PL
Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.
Van Wart SA; Forrest A; Khariton T; Rubino CM; Bhavnani SM; Reynolds DK; Riccobene T; Ambrose PG
J Clin Pharmacol; 2013 Nov; 53(11):1155-67. PubMed ID: 23907740
[TBL] [Abstract][Full Text] [Related]
35. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
[TBL] [Abstract][Full Text] [Related]
36. Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia.
Lee YR; Jacobs KL
Drugs; 2019 Nov; 79(17):1867-1876. PubMed ID: 31705486
[TBL] [Abstract][Full Text] [Related]
37. Omadacycline: a therapeutic review of use in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Chopra T; Sandhu A; Theriault N; Meehan J; Tillotson G
Future Microbiol; 2020 Sep; 15():1319-1333. PubMed ID: 32959689
[TBL] [Abstract][Full Text] [Related]
38. The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model.
Lodise TP; Tillotson GS; Spargo A; Bozkaya D; Massey J
Clin Drug Investig; 2020 Oct; 40(10):961-971. PubMed ID: 32651832
[TBL] [Abstract][Full Text] [Related]
39. [Ceftaroline fosamil, a broad spectrum cephalosporin antibiotic for the treatment of community-acquired pneumonia and complicated skin and skin structure infections].
Nikitin AV
Antibiot Khimioter; 2011; 56(7-8):47-9. PubMed ID: 22359871
[No Abstract] [Full Text] [Related]
40. Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post-hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Trial.
LoVecchio F; Schranz J; Alexander E; Mariano D; Meads A; Sandrock C; Moran GJ; Giordano PA
J Emerg Med; 2021 Jun; 60(6):781-792. PubMed ID: 33731270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
